Clinical Trials Directory

Trials / Completed

CompletedNCT06652035

Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies

Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia

Status
Completed
Phase
Study type
Observational
Enrollment
161 (actual)
Sponsor
Liaquat University of Medical & Health Sciences · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Detailed description

In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTQuevir® (Quercetin Phytosome®)500 mg Quevir® (Quercetin Phytosome®) tablet
DIETARY_SUPPLEMENTBactoblis®Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)

Timeline

Start date
2021-09-01
Primary completion
2022-12-31
Completion
2023-06-15
First posted
2024-10-22
Last updated
2024-10-29

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06652035. Inclusion in this directory is not an endorsement.